Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.
Open Access
- 1 January 1986
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 21 (1) , 63-69
- https://doi.org/10.1111/j.1365-2125.1986.tb02823.x
Abstract
The pharmacokinetics of enalaprilat were studied after administration of single and multiple doses of enalapril maleate to people with normal and impaired renal function. Renal impairment was associated with higher serum concentrations of enalaprilat, longer times to peak concentrations, slower decline of serum concentrations and with reduced urinary elimination. Urinary elimination of enalaprilat was closely related to renal function. In patients with severe renal impairment (GFR values below 30 ml min-1 1.73 m-2) significantly smaller doses of enalapril maleate will be required than in patients with normal or less severely impaired renal function.This publication has 8 references indexed in Scilit:
- Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteersBiopharmaceutics & Drug Disposition, 1984
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982
- THE PHYSIOLOGICAL DISPOSITION AND METABOLISM OF ENALAPRIL MALEATE IN LABORATORY-ANIMALS1982
- EFFECT OF N-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-ALA-L-PRO AND ITS ETHYL-ESTER (MK-421) ON ANGIOTENSIN CONVERTING ENZYME INVITRO AND ANGIOTENSIN-I PRESSOR-RESPONSES INVIVO1981
- A new class of angiotensin-converting enzyme inhibitorsNature, 1980
- Clinical pharmacology and the elderly patientPublished by Springer Nature ,1980
- Digoxin Metabolism in the ElderlyCirculation, 1969